Telix to buy ARTMS in $82M deal
Telix Pharmaceuticals has entered an agreement to acquire Canadian diagnostic imaging isotopes company ARTMS for $82 million.
Under the agreement, Telix will take on ARTMS’ cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultrapure rare metals such as zinc-68, which is irradiated to produce gallium-68. The companies have been collaborating since 2020 to develop higher curie-scale production of Illuccix, a PET radiotracer injection kit used for prostate cancer imaging.
ARTMS is based in Burnaby, British Columbia, and is a privately held spin-off company of TRIUMF, Canada's particle acce...
Source: AuntMinnie.com Headlines - March 6, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Namibia: Prostate Cancer the Leading Cancer in Namibia
[New Era] The International Agency for Research on Cancer (IARC), through the Global Cancer Observatory (GCO), recently announced that prostate cancer is Namibia's leading malignancy. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 5, 2024 Category: African Health Tags: Health and Medicine Namibia Southern Africa Source Type: news
My prostate tumour had no symptoms. If my wife hadn't made me see a doctor, it could have been fatal, reveals Steve Rider
Last autumn, after a 45-year career in sports broadcasting 'without a single day off through ill health', Steve Rider learned he had prostate cancer - and it could kill him if he didn't act fast. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2024 Category: Consumer Health News Source Type: news
Steve Rider's prostate tumour had no symptoms. If his wife hadn't made him see a doctor, it could have been fatal
Last autumn, after a 45-year career in sports broadcasting 'without a single day off through ill health', Steve Rider learned he had prostate cancer - and it could kill him if he didn't act fast. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2024 Category: Consumer Health News Source Type: news
Outside the Guidelines: Denosumab Overuse in Prostate Cancer Outside the Guidelines: Denosumab Overuse in Prostate Cancer
Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 4, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Men who wake in the night for 30 minutes are 20 per cent more likely to get prostate cancer, study reveals
Men who wake in the night are 20 per cent more likely to develop prostate cancer , a study has revealed. Researchers found that broken sleep patterns could be a major risk for the onset of the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - March 3, 2024 Category: Consumer Health News Source Type: news
Ask Dr Rosemary Leonard: 'Why won’t my GP give me prostate cancer blood tests?'
GP Dr Rosemary Leonard answers Express readers' medical queries (Source: Daily Express - Health)
Source: Daily Express - Health - March 1, 2024 Category: Consumer Health News Source Type: news
PSA Test Might Overdiagnose Prostate Cancers in Black Men
FRIDAY, March 1, 2024 -- A new British study suggests that the prostate-specific antigen (PSA) test, long used to spot prostate cancers, might lead to overdiagnosis in Black men.Researchers now theorize that Black men may have naturally higher... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 1, 2024 Category: General Medicine Source Type: news
Study Tests Office-Based Transperineal Approach to Prostate Biopsies
(MedPage Today) -- A multicenter randomized trial compared transperineal prostate biopsy without antibiotic prophylaxis versus transrectal biopsy with targeted prophylaxis, examining infections, prostate cancer detection, pain, and other measures... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 29, 2024 Category: Hematology Source Type: news
Report: Second type of prostate cancer identified by AI
New research by two British universities has identified a new aggressive form of prostate cancer using artificial intelligence, which could change the way the disease is found and treated. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 29, 2024 Category: Consumer Health News Source Type: news
GE HealthCare features new ultrasound, MRI offerings at ECR 2024
VIENNA – GE HealthCare (GEHC) is highlighting a revamped ultrasound product line, the European launch of its Signa Champion 1.5-tesla MRI scanner, and its Care Pathways program in its exhibit area at ECR 2024.
In ultrasound, GEHC is debuting Logiq Totus, a midrange, full-body scanner designed for use in a variety of clinical scenarios. Totus includes technology that was previously only available on its higher-end systems, such as its cSound architecture, according to the vendor.
Totus features AI-powered voice control as well as decision support via Breast and Thyroid Assistant software from GEHC partner Koios. It’s ...
Source: AuntMinnie.com Headlines - February 29, 2024 Category: Radiology Authors: Erik L. Ridley Tags: Clinical News Ultrasound Source Type: news
Prostate cancer is NOT just one disease: Huge breakthrough as scientists discover illness is actually split into two types - and it could save thousands of lives
The team, led by researchers at the University of Oxford and the University of Manchester, used AI to study DNA changes in prostate cancer samples. (Source: the Mail online | Health)
Source: the Mail online | Health - February 29, 2024 Category: Consumer Health News Source Type: news
Study offers hope in identifying high-risk prostate cancer patients
Researchers find way to classify prostate cancer that might help identify 15% of men with more aggressive typeThe most common type of prostate cancer has two distinct ways of developing in the body, researchers have found, opening up new possibilities for identifying which patients need treatment.Prostate cancer is the most common form of cancer in men, withone in eight diagnosed with the disease during their lifetime. Most prostate cancersare adenocarcinomas– a type of cancer that forms in the glandular tissue that lines certain internal organs. But while the disease can kill, for many patients the risk is low.Continue ...
Source: Guardian Unlimited Science - February 29, 2024 Category: Science Authors: Nicola Davis Science correspondent Tags: Prostate cancer Society Cancer research Science Medical research UK news Health Men Source Type: news
Radiologists and AI-powered health informatics: Leading the way in screening
Sham Sokka, chief operating and technology officer of DeepHealth, discusses why he is excited about this year’s ECR congress in Vienna.
What are you most excited about for ECR this year?
Vienna is such a beautiful city and I’m so excited to be here at The European Congress of Radiology (ECR 2024) again this year.
At DeepHealth, this represents an exciting time – to showcase our pioneering offering, present new data, and meet and network with experts in the field of screening and radiology. I always relish the opportunity to talk to our customers from around the world.
Everything we do at DeepHealth is about empow...
Source: AuntMinnie.com Headlines - February 29, 2024 Category: Radiology Authors: DeepHealth Tags: Artificial Intelligence Source Type: news
Janux Stock Launches 230% On Its'Significant Opportunity' In Prostate Cancer Treatment
(Source: Reuters: Health)
Source: Reuters: Health - February 28, 2024 Category: Consumer Health News Source Type: news
